A retrospective study investigating safety and usage of direct oral anticoagulants (dabigatran, rivaroxaban and apixaban) for the treatment of venous thromboembolism in the oncology population
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology